The Canada Next-generation Sequencing Market was valued at $405.2 Million in 2026 and projected to reach to $744 Million by 2031, representing a compound annual growth rate of 12.9%. Canada's next-generation sequencing market is poised for sustained expansion through 2031, driven by increasing integration of NGS into clinical diagnostics and personalized medicine protocols.
Canada's NGS market is valued at $405.2 million in 2026 and is projected to reach $744.0 million by 2031, representing a robust 12.9% CAGR driven by increased adoption of genomic testing and precision medicine initiatives.
Canada's publicly funded healthcare system and strong biotechnology ecosystem are accelerating NGS adoption across academic medical centers, hospitals, and diagnostic laboratories, positioning the country as a leader in genomic research.
Significant government and private sector investments in precision medicine programs and genomic research initiatives are expanding NGS applications in oncology, rare disease diagnosis, and pharmacogenomics across Canadian healthcare institutions.
Canada's NGS market is characterized by growing participation from both international sequencing companies and domestic biotech firms, with increasing partnerships between Canadian research institutions and global genomics leaders.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 14.5% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 13.93 (2026) |
| Revenue Forecast (Billions) | ~USD 27.41 (2031) |
| Segments Covered | Offering, Type, Technology, Workflow, End User, Application |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| DNA LINK | South Korea | Public Company | Whole genome and De Novo sequencing,Whole exome and targeted sequencing,Transcriptome and single-cell RNA sequencing, |
| WUXI APPTEC | China | Public Company | WuXi Chemistry (small molecules, oligos, peptides, conjugates),WuXi Testing (toxicology, DMPK, bioanalytical, other lab testing),WuXi Biology (discovery biology, target-to-candidate services), |
| THERAGEN ETEX CO., LTD. | South Korea | Public Company | Circulatory and metabolic drugs,Respiratory and digestive therapies,Antibiotics and antifungals, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems, |
| GENOMICS BIOSCI & TECH. CO., LTD. | Taiwan | Public Company | Clinical testing (reproductive health and cancer),Sequencing, synthesis, genomics and proteomics services,CDMO (contract development and manufacturing), |
| INTEGRAGEN SA | France | Public Company | Genomic pharma and research sequencing services (oncology and rare disease),MERCURY oncology interpretation platform,Galileo RNA-Seq exploration and related analytics, |
| CENTOGENE AG | Germany | Public Company | Genetic sequencing and diagnostics (WES, WGS, NGS assays including NEW CentoGenome),Multiomic solutions (CENTOGENE MOx 2.0 and biochemical/RNA integration),Pharma solutions (target/drug screening, clinical development, market access, patient recruitment), |
| PERSONALIS, INC. | United States | Public Company | Pharma and biopharma services (ImmunoID NeXT, WES/WGS, translational research and clinical trials),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related physician-ordered tests), |
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (culture media, VITEK, VIRTUO, ETEST, API, VITEK REVEAL),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables), |
| REVVITY | United States | Public Company | Diagnostics instruments and reagents (prenatal, neonatal, infectious disease, specialty immunodiagnostics),Life science reagents and assay platforms (immunology, cell analysis, proteomics),Genomic workflows and NGS-related tools, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing, Assurance, and Certification,Environment and Maritime Testing,Biopharma Testing and PSS Insourcing, |
| PACBIO | United States | Public Company | Long-read instruments (Revio, Sequel, Vega),Long-read consumables and SMRT reagents,Short-read sequencing (Onso) and related consumables, |
| OXFORD NANOPORE TECHNOLOGIES PLC | United Kingdom | Public Company | PromethION systems and consumables,MinION and portable platforms,GridION and mid-throughput systems, |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing), |
| BD | United States | Public Company | Medical Essentials (vascular access, syringes, needles, sharps, enteral),Connected Care (infusion therapy, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, assays), |
DNA LINK is a South Korean public company founded in 2000 with 84 employees, operating in the genomics and biotechnology sector.
WUXI APPTEC is a Chinese public company founded in 2000 with 33,834 employees, providing pharmaceutical research and development services.
THERAGEN ETEX CO., LTD. is a South Korean public company founded in 1987 with 224 employees, specializing in genomics and genetic testing.
SYSMEX CORPORATION is a Japanese public company founded in 1968 with 10,861 employees, providing diagnostic and laboratory equipment solutions.
GENOMICS BIOSCI & TECH. CO., LTD. is a Taiwanese public company founded in 2001, operating in the genomics and biotechnology industry.
INTEGRAGEN SA is a French public company founded in 2000 with 37 employees, specializing in genomics and genetic analysis.
CENTOGENE AG is a German public company founded in 2006 with 384 employees, providing genetic testing and diagnostic services.
PERSONALIS, INC. is a United States-based public company founded in 2011 with 260 employees, specializing in genomic sequencing and analysis.
BIOMERIEUX S.A. is a French public company founded in 1963 with 14,894 employees, providing in vitro diagnostics and microbiology solutions.
ILLUMINA, INC. is a United States-based public company founded in 1998 with 8,625 employees, a leading provider of DNA sequencing and genetic analysis platforms.
THERMO FISHER SCIENTIFIC INC. is a United States-based public company founded in 1956 with 125,000 employees, providing life sciences research and diagnostic products and services.
AGILENT TECHNOLOGIES, INC. is a United States-based public company founded in 1999 with 18,000 employees, offering analytical instruments and life sciences solutions.
QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees, providing molecular diagnostics and life sciences research tools.
DANAHER CORPORATION is a United States-based public company founded in 1969 with 59,000 employees, operating a diversified conglomerate including life sciences and diagnostics.
REVVITY is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
EUROFINS SCIENTIFIC is a Luxembourg-based public company founded in 1987 with 65,694 employees, providing laboratory testing and scientific services globally.
PACBIO is a United States-based public company founded in 2000 with 485 employees, specializing in long-read DNA sequencing technology.
OXFORD NANOPORE TECHNOLOGIES PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees, developing nanopore-based DNA and RNA sequencing technology.
TAKARA BIO INC. is a Japanese private company founded in 2002 with 1,779 employees, providing biotechnology products and services for research and diagnostics.
BD is a United States-based public company founded in 1897 with 72,000 employees, providing medical devices, diagnostics, and life sciences solutions.
10X GENOMICS is a United States-based public company founded in 2012 with 1,178 employees, developing single-cell and spatial genomics technologies.
Canada's next-generation sequencing market is projected to reach $744.0 million by 2031, growing from $405.2 million in 2026.
Canada's NGS market is expected to grow at a compound annual growth rate of 12.9% between 2026 and 2031.
Key drivers include government research funding, healthcare system integration, declining sequencing costs, expanded insurance coverage, and rising demand for precision medicine in Canada.
Clinical diagnostics, oncology, and genetic disorder screening are the primary applications driving Canada's NGS market expansion through 2031.
Canada's 12.9% CAGR is slightly below the global average of 14.5%, reflecting a mature but steadily growing market with strong healthcare infrastructure.
This study of the next-generation sequencing market relied on secondary sources, directories, and databases to gather pertinent information. To collect and validate key qualitative and quantitative data and to evaluate market growth prospects, in-depth interviews were conducted with numerous primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the next-generation sequencing market using several research strategies, the final market size was derived by triangulating data from primary research.
Secondary sources for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), the National Human Genome Research Institute (NHGRI), the International Agency for Research on Cancer (IARC), the National Institute for Infectious Diseases (IRCCS), the Association for Clinical Genomic Science (ACGS), the American Society of Human Genetics (ASHG), the European Society of Human Genetics (ESHG), the Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, the Biotechnology and Biological Sciences Research Council (BBSRC), the Organisation for Economic Co-operation and Development (OECD), Genome Research, the National Cancer Institute (NCI), the European Medicines Agency (EMA), the Population Health Research Institute (PHRI), PubMed, the World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data were collected and analyzed to determine the overall size of the global next-generation sequencing market, which was validated through primary research.
Extensive primary research was conducted after acquiring basic knowledge of the global next-generation sequencing market through secondary research. Several primary interviews were conducted with market experts from the supply side, including C-level and D-level executives, operational managers, and marketing & sales managers at key manufacturers, distributors, and channel partners of companies providing NGS; and from the demand side, including personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both, the top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments within the market. The research methodology for estimating market size includes the following.

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Next-generation sequencing (NGS) refers to non-Sanger-based, high-throughput DNA sequencing technologies. These technologies sequence DNA strands simultaneously, yielding substantially higher throughput and reducing the need for fragment-cloning methods often used in Sanger genome sequencing. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
Company Information
Segment Analysis
Full forecast, segment splits, and company analysis for all Next-generation Sequencing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report